I frame GLP-1 therapy as an adjunct, not a replacement, for dermatologic systemic treatment
Our newest Prescription Drug Freight Fraud Report analyzes November and December 2025 import data and reveals a surge of social-media-driven medications entering the U.S
KLOW is designed for individuals or research subjects with a higher inflammatory burden, systemic stress, or complex recovery needs
Lingli Dong, [email protected] These authors have contributed equally to this work This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Riederer et al., 2011)
Recent FDA approvals have included indications for cardiovascular risk reduction, and others are anticipated for conditions like obstructive sleep apnea and chronic kidney disease
